Idorsia Makes Progress With Quviviq, But Needs Cash To Fund Big R&D And Launch Spending

Idorsia has a serious cashflow problem because of major R&D and drug launch commitments, but is banking on its blockbuster bets coming good, including two potential first-in-class cardiovascular drugs.